Literature DB >> 27057408

Dextromethorphan/Quinidine For Neuropsychiatric Manifestations of Wilson's Disease.

Justin Faden1, John P O'Reardon1.   

Abstract

Entities:  

Year:  2015        PMID： 27057408      PMCID： PMC4805409          DOI： 10.4088/PCC.15l01820

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  6 in total

Review 1.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury.

Authors:  John P Daly; Jason P Caplan
Journal:  Psychosomatics       Date:  2012-03-27       Impact factor: 2.386

Review 3.  Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Authors:  Howard Rosen
Journal:  Drugs Today (Barc)       Date:  2008-09       Impact factor: 2.245

Review 4.  Wilson's disease and other neurological copper disorders.

Authors:  Oliver Bandmann; Karl Heinz Weiss; Stephen G Kaler
Journal:  Lancet Neurol       Date:  2015-01       Impact factor: 44.182

5.  Quality of Life and Psychiatric Symptoms in Wilson's Disease: the Relevance of Bipolar Disorders.

Authors:  Mg Carta; G Mura; O Sorbello; G Farina; L Demelia
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-09-18

Review 6.  Antitussives and substance abuse.

Authors:  Jarrett M Burns; Edward W Boyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.